MedPAC, an independent panel of experts that advises lawmakers on payment policy, is endorsing an additional 0.5% update to doc pay, the AMA reports.  

Chief Executive Officer Dana Smetherman, MD, discusses the college's efforts to push forward several bills related to radiology.
 

DocMoonlight, the nation’s largest provider of onsite contrast supervision, and ContrastConnect, the largest provider of virtual contrast supervision, today announced a strategic collaboration designed to offer imaging organizations the most complete, flexible, and scalable contrast supervision solution in the industry. By aligning their complementary strengths, the partnership is aimed at expanding patient access, enhancing patient safety, and meeting growing imaging demands across diverse regulatory environments.

A mother in Georgia alleges the problematic prenatal ultrasound findings forced her care team to make medical decisions resulting in her child being born with lifelong disabilities. 

Boston Medical Center has sought to have patients self-identify for lung cancer screening, administering multilingual surveys while they wait for imaging appointments. 

Diagnostic Radiology & Imaging—formerly Greensboro Imaging—has selected former Raleigh Radiology CEO Frank Manole, DNP, MBA, to fill the key role.  

Experts believe the system has the potential to "dramatically improve access, speed and accuracy, especially for women with dense breasts.” 

CMS has made it a priority to increase payments for procedures performed by office-based labs and ambulatory surgical centers. This was reflected in policy changes made as part of the 2026 Medicare Physicians Fee Schedule.

The California-based health system faced multiple accusations of upcoding diagnoses to receive additional risk-adjusted payments from the Medicare Advantage program. Its payer plan and providers were implicated in what the DOJ described as systemic fraud. Kaiser Permanente denies any wrongdoing.

President Trump’s outline is largely an exercise in thinking out loud since it can’t propel anything consequential without legislative action in Congress. Still, the plan—and the reactions it’s eliciting—warrant a look. 

This is a cash and stock transaction that values Penumbra at $374 per share. The move helps Boston Scientific expand its vascular and neurovascular portfolios, gaining new treatments for pulmonary embolism, stroke, deep vein thrombosis and many other critical cardiovascular conditions.